Dr. Brion Randolph, MD
Claim this profileArea of expertise
Follicular Lymphoma
Brion Randolph, MD has run 1 trial for Follicular Lymphoma. Some of their research focus areas include:
More about Brion Randolph, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Brion Randolph, MD has experience with
- Oncoquest-L Vaccine
Breakdown of trials Brion Randolph, MD has run
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brion Randolph, MD specialize in?
Brion Randolph, MD focuses on Follicular Lymphoma and other conditions. In particular, much of their work with Follicular Lymphoma has involved Stage III patients, or patients who are Stage IV.
Is Brion Randolph, MD currently recruiting for clinical trials?
No, Brion Randolph, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Brion Randolph, MD has studied deeply?
Yes, Brion Randolph, MD has studied treatments such as Oncoquest-L vaccine.
What is the best way to schedule an appointment with Brion Randolph, MD?
Apply for one of the trials that Brion Randolph, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.